Telix completes patient enrollment in Phase 3 BiPASS study
Telix Pharmaceuticals Limited announced completion of patient enrollment in its Phase 3 BiPASS study for commercial PSMA-PET1 imaging agents, Illuccix.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.